Zobrazeno 1 - 3
of 3
pro vyhledávání: '"K. G. Babina"'
Autor:
M. I. Volkova, A. S. Kalpinskiy, P. S. Borisov, O. I. Evsyukova, A. S. Olshanskaya, V. B. Matveev, B. Ya. Alekseev, E. V. Peganova, A. F. Nasretdinov, E. V. Lymar, E. G. Ovchinnikova, T. A. Sveklina, E. A. Usynin, A. M. Abdelgafur, E. A. Tararova, L. M. Shumova, A. S. Belenkov, I. Yu. Dolgov, N. G. Ponomareva, I. V. Evstigneeva, A. N. Ivanov, A. R. Isaev, R. V. Leonenkov, A. V. Meskikh, M. R. Mukhitova, S. A. Orlova, I. V. Teslenok, M. M. Shegurova, M. T. Aivazov, Z. V. Amoev, K. G. Babina, A. A. Vorontsova, E. V. Karabina, N. V. Kirdakova, I. E. Shumskaya, G. P. Kolesnikov, E. S. Kuzmina, D. Kh. Latipova, E. S. Lyutova, M. M. Fael, A. N Chugarova, A. S. Antipin
Publikováno v:
Onkourologiâ, Vol 17, Iss 1, Pp 31-44 (2021)
Objective. The primary endpoint was progression-free survival; secondary endpoints included overall survival, objective response rate and duration, tumor control rate and duration, as well as safety profile of lenvatinib with everolimus in consecutiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b91177b36520353fff8907e4b001ccdd
https://doi.org/10.17650/1726-9776-2021-17-1-31-44
https://doi.org/10.17650/1726-9776-2021-17-1-31-44
Publikováno v:
Современная онкология, Vol 16, Iss 4, Pp 21-23 (2014)
Trastuzumab in combination with standard chemotherapy has shown its effectiveness in treating HER2-positive metastatic gastric cancer. The median overall survival in its application is 16,8 months compared with 11,8 months when chemotherapy using alo
Externí odkaz:
https://doaj.org/article/0d27733eafb24e0895585d54f7da7d33
Autor:
M. I. Volkova, A. M. Abdelgafur, M. T. Aivazov, Z. V. Amoev, K. G. Babina, P. S. Borisov, A. A. Vorontsovа, I. V. Evstigneeva, O. I. Evsyukova, O. V. Zhelezin, A. S. Kalpinsky, E. V. Karabina, N. V. Kirdakova, G. P. Kolesnikov, E. S. Kuzmina, D. Kh. Latipova, R. V. Leonenkov, M. R. Maturov, A. V. Meskikh, S. V. Mishugin, E. G. Ovchinnikova, A. S. Olshanskaya, S. A. Protsenko, T. Yu. Semiglazova, R. V. Smirnov, E. A. Usynin, M. M. Fael, E. M. Cherniakova, I. E. Shumskaya
Publikováno v:
Onkourologiâ, Vol 15, Iss 3, Pp 56-69 (2019)
Objective: an assessment of efficacy and safety of lenvatinib in combination with everolimus in unselected patients with metastatic renal cell carcinoma (mRCC) progressed during or following ≥1 line of antiangiogenic targeted therapy.Material. Russ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13d301a22b53e5e52911c9452451cbb9
https://oncourology.abvpress.ru/oncur/article/view/984
https://oncourology.abvpress.ru/oncur/article/view/984